What if you could know before a clinical trial which patients will respond? Not after Phase 2 fails. Not after spending $50M. Before you even start.
In this episode, Pilgrim Jackson, CEO of Yatiri Bio, shares how his company is using proteomics to predict treatment response in AML and ovarian cancer with 100% accuracy so far.
What we discuss:
• How proteomic signatures differentiate responders from non-responders in AML and ovarian cancer
• Why this could reduce Phase 2 trial enrollment from 100 patients to 40—cutting costs in half
• De-risking clinical trial design and addressing patient heterogeneity
• Regulatory considerations for biomarker-driven and stratified trials
• The future of precision oncology and patient-centric trial design
This isn't incremental improvement. This is a completely different way to run trials.
About the Guest: Pilgrim Jackson is CEO of Yatiri Bio, a biotechnology company decoding proteins to predict treatment response in oncology.
About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.
🔗 Connect:
• Yatiri Bio: [https://yatiribio.com]
• Pilgrim Jackson:[https://www.linkedin.com/in/pilgrimjackson]
• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]
📧 Questions or guest suggestions? [jeffreytrickett@gmail.com]
#Biotech #ClinicalTrials #PrecisionMedicine #Proteomics #Oncology #AML #DrugDevelopment
Sneak Peek from episode VII of my video podcast: Innovating Tomorrow’s Medicine ft. Pilgrim Jackson, CEO of Yatiri Bio Inc. decoding proteins to predict treatment response in Acute Myeloid Leukemia (AML) and Ovarian Cancer.
In this exclusive preview, Pilgrim shares a glimpse into: What proteomic signatures they have found that differentiate responders from non-responders in AML and ovarian cancer. De-risking clinical trial design in oncology, especially with regard to patient heterogeneity.
➡️ Full episode launches on 18 December
🔔 Subscribe and hit the bell so you don’t miss it!
🎙️ About the Show:
Innovating Tomorrow’s Medicine features bold conversations with pioneers shaping the future of healthcare, biotechnology, and life sciences.
📌 Stay tuned for the full interview where we explore and share unique insights:
– What inspired the founding of Yatiri Bio Inc. and decoding proteins to predict treatment response
– Why they chose to focus on AML and ovarian cancer as lead indications
– Proteomics in Oncology
– Targets, Modalities & Resistance
– regulatory strategy, when it comes to stratified trials or biomarker-linked therapies
– Personal reflections and future outlook
#SneakPeek
#PilgrimJackson
#YatiriBio
#FutureOfMedicine
What if we could help millions quit smoking with a naturally derived compound that's been used for decades—but never brought to the U.S. market until now?
In this episode, Rick Stewart, CEO of Achieve Life Sciences, shares how cytisinicline is redefining smoking cessation after receiving FDA acceptance for its New Drug Application (NDA)—a major milestone in the fight against nicotine dependence.
What we discuss:
• FDA acceptance for the cytisinicline New Drug Application (NDA) and what comes next
• Why cytisinicline represents a breakthrough in smoking cessation
• Commercial readiness and go-to-market strategy
• Financial strategy and capital efficiency in late-stage biotech
• Market impact and public health implications of a new smoking cessation therapy
• Investor relations and communicating clinical value to stakeholders
• Personal reflections on leadership and building Achieve Life Sciences
This isn't just another smoking cessation drug. This is a naturally derived therapeutic with the potential to transform public health and save lives at scale.
About the Guest: Rick Stewart is CEO of Achieve Life Sciences, a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence.
About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.
🔗 Connect:
• Achieve Life Sciences: [https://achievelifesciences.com]
• Rick Stewart: [https://www.linkedin.com/in/rick-stewart-9597654]
• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]
📧 Questions or guest suggestions? [jeffreytrickett@gmail.com]
#Biotech #SmokingCessation #Cytisinicline #PublicHealth #DrugDevelopment #FDA #NDA #ClinicalTrials
Sneak Peek: Innovating Tomorrow’s Medicine ft. Rick Stweart.In this exclusive preview, Rick shares a glimpse into Achieve Life Sciences and Cytisinicline which is redefining the future of nicotine dependence.➡️ Full episode launches on 4 December 🔔 Subscribe and hit the bell so you don’t miss it!🎙️ About the Show:Innovating Tomorrow’s Medicine features bold conversations with pioneers shaping the future of healthcare, biotechnology, and life sciences.📌 Stay tuned for the full interview where we explore and share unique insights:– FDA acceptance for its cytisinicline New Drug Application (NDA)– Commercial Readiness– Financial strategy and capital efficiency– Market impact and public health–Engagement and investor relations – Personal reflections and futureoutlook#SneakPeek#Rick Stewart#FutureOfMedicine
Full Episode: Innovating Tomorrow’s Medicine ft. Sheila Gujrathi, MD, biotech entrepreneur and executive, healthcare investor, and drug developer with over 25 years of experience in the industry. She’s founded, built, and run numerous biotech companies, and led the development and approval of life-changing pharmaceutical drugs, including Orencia® and Nulojix®.In this episode, Sheila shares a glimpse into:The Spiritual Foundation of Biotech Leadership and "The Mirror Effect" a new book and leadership framework that just launched on 4 November 2025 and is already officially an Amazon Bestseller.➡️ Full episode launches on 20 November 🔔 Subscribe and hit the bell so you don’t miss it!🎙️ About the Show:Innovating Tomorrow’s Medicine features bold conversations with pioneers shaping the future of healthcare, biotechnology, and life sciences.📌 Stay tuned for the full interview where we explore and share unique insights:– The Spiritual Foundation of Biotech Leadership – Deal-Making & Corporate Strategy– The Science & the Pipeline– Diversity, Inclusion & the Biotech CEO Sisterhood – Personal reflections and future outlook#SneakPeek#SheilaGujrathi#FutureOfMedicine
Sneak Peek: Innovating Tomorrow’s Medicine ft. Sheila Gujrathi, MD, biotech entrepreneur and executive, healthcare investor, and drug developer with over 25 years of experience in the industry. She’s founded, built, and run numerous biotech companies, and led the development and approval of life-changing pharmaceutical drugs, including Orencia® and Nulojix®.In this exclusive preview, Sheila shares a glimpse into:The Spiritual Foundation of Biotech Leadership and "The Mirror Effect" a new book and leadership framework that just launched on 4 November 2025 and is already officially an Amazon Bestseller.➡️ Full episode launches on 20 November 🔔 Subscribe and hit the bell so you don’t miss it!🎙️ About the Show:Innovating Tomorrow’s Medicine features bold conversations with pioneers shaping the future of healthcare, biotechnology, and life sciences.📌 Stay tuned for the full interview where we explore and share unique insights:– The Spiritual Foundation of Biotech Leadership – Deal-Making & Corporate Strategy– The Science & the Pipeline– Diversity, Inclusion & the Biotech CEO Sisterhood – Personal reflections and future outlook#SneakPeek#SheilaGujrathi#FutureOfMedicine
What if we could bring the power of precision medicine to more cancer patients, faster—using AI to match patients with the right treatments at the right time?
In this episode, Rick Fultz, CEO of Acurion, shares how his company is transforming precision oncology by combining next-generation science with artificial intelligence to deliver personalized cancer care at scale.
What we discuss:
• The vision behind Acurion and its mission in precision oncology
• How AI and machine learning are revolutionizing cancer treatment selection
• Moving beyond traditional biomarker approaches to comprehensive patient profiling
• Fundraising strategies and building investor confidence in AI-driven healthcare
• Leadership and culture: building a team capable of transforming cancer care
• Challenges and opportunities in scaling precision medicine
• Personal reflections on the future of oncology and patient outcomes
This isn't incremental innovation. This is about fundamentally changing how we match patients with cancer therapies.
About the Guest: Rick Fultz is CEO of Acurion, Inc., a precision oncology company whose mission is to bring the power of precision medicine to more cancer patients, faster.
About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.
🔗 Connect:
• Acurion: [https://acurionhealth.com]
• Rick Fultz: [https://www.linkedin.com/in/rickfultz]
• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]
📧 Questions or guest suggestions? [jeffreytrickett@gmail.com]
#Biotech #PrecisionMedicine #Oncology #ArtificialIntelligence #Cancer #MachineLearning #DrugDevelopment #PersonalizedMedicine
Sneak Peek: Innovating Tomorrow’s Medicine ft. Rick Fultz, CEO of Acurion, Inc. whose mission is to bring the power of precision medicine to more cancer patients, faster.In this exclusive preview, Rick shares a glimpse into how Acurion is transforming the field of precision oncology using next-generation science and strategic biotech leadership.➡️ Full episode launches on 30 October 🔔 Subscribe and hit the bell so you don’t miss it!🎙️ About the Show:Innovating Tomorrow’s Medicine features bold conversations with pioneers shaping the future of healthcare, biotechnology, and life sciences.📌 Stay tuned for the full interview where we explore and share unique insights:– The vision behind Acurion – New approaches using AI in precision medicine– Fund raising– Leadership and culture– Personal reflections and future outlook#SneakPeek#RickFultz#Acurion#Biocom#FutureOfMedicine
What if we could use gene editing to treat Duchenne Muscular Dystrophy—not just manage symptoms, but address the underlying genetic cause in a scalable, precise way?
In this episode, Dr. Courtney Young, CEO of MyoGene Bio, shares how her company is using CRISPR technology to transform the treatment landscape for Duchenne Muscular Dystrophy, offering hope to patients and families facing this devastating disease.
What we discuss:
• The vision behind MyoGene Bio and why Duchenne Muscular Dystrophy
• How CRISPR gene editing works and why it's uniquely suited for Duchenne
• Scalability, precision, and safety considerations in gene editing therapies
• Navigating the regulatory pathway for CRISPR-based treatments
• Fundraising in the gene editing space and building investor confidence
• Leadership and culture: building a mission-driven biotech company
• Personal reflections on the future of gene therapy and rare disease treatment
This isn't just about treating one disease. This is about proving what's possible when gene editing meets rare disease—and opening the door for countless others.
About the Guest: Dr. Courtney Young is CEO of MyoGene Bio, a gene therapy company developing CRISPR-based treatments for Duchenne Muscular Dystrophy.
About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.
🔗 Connect:
• MyoGene Bio: [https://www.myogenebio.com]
• Courtney Young: [https://www.linkedin.com/in/courtney-young-mgb]
• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]
📧 Questions or guest suggestions? [jeffreytrickett@gmail.com]
#Biotech #CRISPR #GeneEditing #DuchenneMuscularDystrophy #RareDisease #GeneTherapy #PrecisionMedicine #Innovation
Sneak Peek – Innovating Tomorrow’s Medicine ft. Dr. Courtney Young, CEO of MyoGene Bio.
In this exclusive preview, Dr. Courtney Young shares a glimpse into how MyoGene Bio is transforming the field of Duchenne Muscular Dystrophy using the gene editing technology CRISPR.
➡️ Full episode launches on 11 September
🔔 Subscribe and hit the bell so you don’t miss it!
🎙️ About the Show: Innovating Tomorrow’s Medicine features bold conversations with pioneers shaping the future of healthcare, biotechnology, and life sciences.
📌 Stay tuned for the full interview where we explore and share unique insights:
– The vision behind MyoGene Bio
– CRISPR and Duchenne Muscular Dystrophy
– Fund raising
– Leadership and culture
– Personal reflections and future outlook
#SneakPeek #Courtney Young #MyoGene Bio #Biotech #Cancer #FutureOfMedicine
What if we could destroy cancer cells using a completely novel payload—one that doesn't rely on traditional chemotherapy or even antibody-drug conjugates, but instead uses lytic peptides to obliterate tumors?
In this episode, Dr. Stanley Lewis, CEO of A28 Therapeutics, shares how his company is pioneering lytic peptides as a next-generation cancer therapy, offering a fundamentally different approach to killing cancer cells.
What we discuss:
• The vision behind A28 Therapeutics and the science of lytic peptides
• How lytic peptides work differently from traditional cancer payloads
• Why this approach could overcome resistance mechanisms that limit other therapies
• The role of AI and machine learning in drug discovery and peptide design
• Fundraising strategies and building investor confidence in novel modalities
• Leadership and culture: assembling a team to tackle cancer differently
• Personal reflections on the future of oncology and transformative therapeutics
This isn't another antibody-drug conjugate. This is a completely different way to kill cancer.
About the Guest: Dr. Stanley Lewis is CEO of A28 Therapeutics, a biotechnology company developing novel lytic peptide-based cancer therapeutics.
About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.
🔗 Connect:
• A28 Therapeutics: [https://a28therapeutics.com]
• Stanley Lewis: [https://www.linkedin.com/in/stanley-t-lewis-md-mph]
• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]
📧 Questions or guest suggestions? [jeffreytrickett@gmail.com]
#Biotech #Cancer #Oncology #LyticPeptides #DrugDiscovery #ArtificialIntelligence #NovelTherapeutics #Innovation
Sneak Peek – Innovating Tomorrow’s Medicine ft. Dr. Stanley Lewis, CEO of A28 Therapeutics.
In this exclusive preview, Dr. Stanley Lewis shares a glimpse into how A28 Therapeutics is transforming the field of cancer using lytic peptides as a novel payload.
➡️ Full episode launches on 28 August
🔔 Subscribe and hit the bell so you don’t miss it!
🎙️ About the Show: Innovating Tomorrow’s Medicine features bold conversations with pioneers shaping the future of healthcare, biotechnology, and life sciences.
📌 Stay tuned for the full interview where we explore and share unique insights:
– The vision behind A28 Therapeutics
– Next-generation payload for cancer therapy
– Role of AI and machine learning in R&D
– Fund raising
– Leadership and culture
– Personal reflections and future outlook
#SneakPeek #StanleyLewis #A28Therapeutics #Biotech #Cancer #FutureOfMedicine
What if we could transform the treatment landscape for rheumatologic diseases by taking bold, innovative approaches that go beyond incremental improvements?
In this episode, Dr. James Mackay, CEO of Crystalys Therapeutics, shares the vision behind launching a new biotech company focused on rheumatology, combining next-generation science with strategic leadership to address unmet patient needs.
What we discuss:
• The vision behind Crystalys Therapeutics and why rheumatology
• New approaches and innovative strategies in treating rheumatologic diseases
• Approach to risk management in early-stage biotech
• Fundraising strategies and building investor confidence from day one
• Leadership and culture: assembling the right team for a startup biotech
• Navigating the competitive landscape in rheumatology
• Personal reflections on entrepreneurship and the future of autoimmune disease treatment
This isn't just another rheumatology company. This is about bringing transformative science to patients who desperately need better options.
About the Guest: Dr. James Mackay is CEO of Crystalys Therapeutics, a biotechnology company developing novel therapeutics for rheumatologic diseases.
About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.
🔗 Connect:
• Crystalys Therapeutics: [https://crystalystx.com]
• James Mackay: [https://www.linkedin.com/in/james-m-mackay]
• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]
📧 Questions or guest suggestions? [jeffreytrickett@gmail.com]
#Biotech #Rheumatology #AutoimmuneDisease #DrugDevelopment #Innovation #Startup #BiotechLeadership
Sneak Peek – Innovating Tomorrow’s Medicine ft. Dr. James Mackay, CEO of Crystalys TherapeuticsIn this exclusive preview, Dr. James Mackay shares a glimpse into how Crystalys Therapeutics is transforming the field of rheumatology using next-generation science and strategic biotech leadership.➡️ Full episode launches on 14 August 🔔 Subscribe and hit the bell so you don’t miss it!🎙️ About the Show:Innovating Tomorrow’s Medicine features bold conversations with pioneers shaping the future of healthcare, biotechnology, and life sciences.📌 Stay tuned for the full interview where we explore and share unique insights:– The vision behind Crystalys Therapeutics – New approaches in rheumatology– Approach to risk management– Fund raising– Leadership and culture– Personal reflections and future outlook#SneakPeek #JamesMackay #CrystalysTherapeutics #Biotech #Rheumatology #FutureOfMedicine
What does it take to transform bold ideas into real-world treatments that save lives?
Welcome to Innovating Tomorrow's Medicine, a podcast that goes beyond the headlines to explore the strategies, insights, and breakthroughs shaping the future of healthcare and biotechnology.
Hosted by Dr. Jeff Trickett—a neuroscientist and biotech strategist—this show features candid conversations with biotech founders, CEOs, researchers, and innovators who are tackling medicine's biggest challenges. From AI-driven diagnostics to gene editing, novel cancer therapies, and precision medicine, each episode delivers substantive discussions about the science, strategy, and leadership driving transformative change.
What you'll discover:
• The vision and science behind breakthrough therapies
• Real talk about fundraising, clinical development, and commercialization
• Leadership insights from those building the future of medicine
• How innovation happens—from lab bench to patient impact
🧬 Bold ideas.
🧠 Visionary innovators.
💡 The science of tomorrow in focus today.
Whether you're in biotech, healthcare, or simply fascinated by medical innovation, this podcast uncovers the strategies behind success and the breakthroughs that will define the future of medicine.
🎧 Subscribe now and join the conversation.
About the Host: Dr. Jeff Trickett is a neuroscientist, biotech strategist, and business development leader with experience spanning drug development, commercial strategy, and portfolio management across biopharma and life sciences.
🔗 Connect:
• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]
• Website: [https://pointlomabiopharma.com]
📧 Questions or guest suggestions? [jeffreytrickett@gmail.com]
#Biotech #Healthcare #Innovation #DrugDevelopment #LifeSciences #Podcast #MedicalInnovation #PrecisionMedicine